(Q43867547)

27 November 2017

title

Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis (English)

1 reference

27 November 2017

0 references

1 reference

7

1 reference

27 November 2017

R Ehling

1

1 reference

27 November 2017

A Lutterotti

2

1 reference

27 November 2017

J Wanschitz

3

1 reference

27 November 2017

M Khalil

4

1 reference

27 November 2017

C Gneiss

5

1 reference

27 November 2017

F Deisenhammer

6

1 reference

27 November 2017

T Berger

8

1 reference

27 November 2017

publication date

1 December 2004

1 reference

Multiple Sclerosis Journal

27 November 2017

published in

1 reference

27 November 2017

volume

10

1 reference

27 November 2017

issue

6

1 reference

27 November 2017

page(s)

601-606

1 reference

Axonal degeneration and progressive neurologic disability in multiple sclerosis

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Detection of autoantibodies to neural antigens in the CSF of Japanese encephalitis patients and correlation of findings with the outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Elevated neurofilament levels in neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Neurofilament protein levels in CSF are increased in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Anti-neurofilament antibodies in blood of patients with neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

Specificity of human anti-neurofilament autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1100OA

10.1191/1352458504MS1100OA

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference